Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Proteasome-Targeted Drug Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PSMA4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMA4 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Theoretical MW confirmed. |
View PSMA4 Products |
| Gene Delivery | PSMA4 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and intracellular localization assays. |
View PSMA4 Products |
| Benchmark Ab | Anti-PSMA4 Recombinant Antibody Recombinant positive control clone for target validation and biochemical assays. |
View PSMA4 Products |
| Validator | PSMA4 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View PSMA4 Products |
| Related Target A | PSMA1 Subfamily homolog for off-target selectivity screening and counter-screening panels. |
View PSMA1 Products |
| Related Target B | PSMB5 Classic proteasome catalytic subunit to evaluate resistance bypass mechanisms. |
View PSMB5 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular Target Accessibility | Lentivirus-driven stable overexpression lines preserve native proteasome complex assembly |
| Subfamily Off-Target Cross-Reactivity | Homolog panel (including PSMA1) strictly verified by mass spectrometry and purity analysis |
| Lack of Controls | Sequence-verified recombinant benchmark antibodies included for assay baseline calibration |
| False Positives in Knockdown | Multi-sequence validated siRNA pool included for high-specificity gene silencing checks |
Live PSMA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSMA4 therapeutics is intensifying, with major players shifting focus from traditional broad-spectrum proteasome inhibitors to subunit-specific small molecules and targeted protein degraders (PROTACs). As first-generation therapies targeting the catalytic beta subunits encounter clinical resistance, the next wave of R&D is targeting the structural alpha subunits, such as PSMA4, to disrupt proteasome assembly or induce selective degradation in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PROTAC / Degrader | Biotech Startups, Academic Labs | Non-Small Cell Lung Cancer (NSCLC) | Degradation kinetics assay (Requires stable cell lines via Lentivirus) |
| Small Molecule Inhibitor | Pharmaceutical Corporates | Glioblastoma, Solid Tumors | Selectivity screening (Requires pure PSMA4 vs PSMA1 proteins) |
| RNA Therapeutics | RNAi Specialists | Refractory Malignancies | Target knockdown validation (Requires validated siRNA pool) |